Colleen Cutcliffe is the CEO and Co-Founder of Pendulum. She has over 15 years of experience leading and managing biology teams in academia, pharmaceuticals and biotechnology. Prior to starting Pendulum, Colleen was the Senior Manager of Biology at Pacific Biosciences and a Scientist at Elan Pharmaceuticals.
Read MoreAndrew Protter, PhD. joined Auransa in January 2017 as Chief Scientific Officer with 35 years of pharmaceutical industry research and development experience. At Auransa, Dr. Protter has led preclinical R&D which uses AI technology to discover novel drug candidates. Auransa’s lead project for hepatocellular carcinoma has completed all IND-supporting preclinical safety studies.
Read More
Dr. Paul R. Billings is a board-certified internist and clinical geneticist, who also holds a PhD in Immunology, from Harvard University. He worked there with Dr. Baruj Benacerraf, who subsequently received the Nobel Prize in Medicine. In 2018, Dr. Billings became the Chief Medical Officer and Senior Vice President for Medical Affairs at Natera.
Read More
JoyL is the General Manager of Pfizer CentreOne, a global contract development and manufacturing organization (CDMO) and a leading supplier of specialty APIs embedded within Pfizer. Nicole is Pfizer CentreOne’s Pipeline Development and Innovation Lead. In this role, Nicole has responsibility for assessing competitive intelligence to identify growth opportunities across the Pfizer CentreOne businesses, lead technical and regulatory assessments of pipeline projects and provide development services to meet customer needs.
Read More
Abbas Kazimi is the Vice President, Head of Business Development at Nimbus Therapeutics, a biotechnology company harnessing quantum mechanics and computational approaches to structural biology to design breakthroughs in medicine.
Read More
Diego is currently the Head of Research & Development of Global Rare Diseases at the Chiesi Group. Before this role, he was leading Chiesi’s development projects in rare diseases and advanced therapies and has more than 10 years experience in drug development, spanning from pre-clinical to commercial phase.
Read More
Dr. Randy Schatzman, Ph.D., is the chief executive officer and a board member of Bolt Biotherapeutics since 2019. He has over 30 years of biotechnology experience. Prior to Bolt, Dr. Schatzman was president and CEO, co-founder and board member of Alder BioPharmaceuticals, Inc. (Nasdaq: ALDR), from 2004 to 2018.
Read More
Dr. Glenn Rosen has spent the bulk of his career engaged in basic and translational research in cancer and fibrosis. From 1993-2014, Dr. Rosen held a tenured faculty position in the Division of Pulmonary and Critical Care Medicine, Department of Medicine, Stanford University.
Read More
Dr. Clayman is a co-founder of Flexion Therapeutics and has served as our President, Chief Executive Officer and as one of our directors since our inception in 2007. Dr. Clayman also serves as the Chairman of the board of directors of both Anokion SA and Ribometrix.
Read More
Dr. Colón brings over 25 years of experience in biopharma, genomics, healthcare and industrial biotechnology. In addition to her role at InCarda, she is Executive Chairman (formerly CEO) of ProterixBio, and serves on the boards of CareDx (NASDAQ:CDNA) and Cocoon Biotech and on the Advisory Board of the Miller Center for Social Entrepreneurship at Santa Clara University.
Read More
Recorded in January 2020, we spoke with Sachin Chandran, who is currently Executive Director and Head of Pharmaceutical Sciences at Catabasis Pharmaceuticals, Inc. in Boston. Sachin’s responsibilities include oversight of CMC, Tech-Ops and supply chain along with matrixed interactions with regulatory, quality, biology, clinical and commercial.
Read More
Mike Novotny is the founder and CEO of Medrio. Mr. Novotny applies 20 years of experience in research and software to his eClinical SaaS vision. Prior to founding Medrio, Mr. Novotny was president of Ninaza, an EDC software company, and had previously held roles as a research associate at the U.N. and a manager of the fraud database at VISA.
Read More